IL247250A0 - Methods and compositions for modulating estrogen receptor mutants - Google Patents
Methods and compositions for modulating estrogen receptor mutantsInfo
- Publication number
- IL247250A0 IL247250A0 IL247250A IL24725016A IL247250A0 IL 247250 A0 IL247250 A0 IL 247250A0 IL 247250 A IL247250 A IL 247250A IL 24725016 A IL24725016 A IL 24725016A IL 247250 A0 IL247250 A0 IL 247250A0
- Authority
- IL
- Israel
- Prior art keywords
- compositions
- methods
- estrogen receptor
- receptor mutants
- modulating estrogen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461952728P | 2014-03-13 | 2014-03-13 | |
| US201461981708P | 2014-04-18 | 2014-04-18 | |
| PCT/EP2015/055120 WO2015136017A1 (en) | 2014-03-13 | 2015-03-12 | Methods and compositions for modulating estrogen receptor mutants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL247250A0 true IL247250A0 (en) | 2016-09-29 |
Family
ID=52682706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL247250A IL247250A0 (en) | 2014-03-13 | 2016-08-11 | Methods and compositions for modulating estrogen receptor mutants |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9855270B2 (en) |
| EP (1) | EP3116496A1 (en) |
| JP (1) | JP2017509631A (en) |
| KR (1) | KR20160132029A (en) |
| CN (1) | CN106488767A (en) |
| AU (1) | AU2015228860A1 (en) |
| BR (1) | BR112016020953A2 (en) |
| CA (1) | CA2941161A1 (en) |
| IL (1) | IL247250A0 (en) |
| MA (1) | MA39740A (en) |
| MX (1) | MX2016011698A (en) |
| RU (1) | RU2016137150A (en) |
| SG (1) | SG11201607339VA (en) |
| WO (1) | WO2015136017A1 (en) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9956276B2 (en) | 2012-01-19 | 2018-05-01 | Duke University | Vaccines against antigens involved in therapy resistance and methods of using same |
| MX2015011132A (en) | 2013-03-14 | 2015-11-30 | Seragon Pharmaceuticals Inc | Polycyclic estrogen receptor modulators and uses thereof. |
| MX2015017655A (en) | 2013-06-19 | 2016-04-15 | Seragon Pharmaceuticals Inc | Estrogen receptor modulator and uses thereof. |
| CA2915534A1 (en) | 2013-06-19 | 2014-12-24 | Seragon Pharmaceuticals, Inc. | Azetidine estrogen receptor modulators and uses thereof |
| US10174381B2 (en) * | 2013-10-18 | 2019-01-08 | The Regents Of The University Of Michigan | Systems and methods for determining a treatment course of action |
| WO2016007499A1 (en) | 2014-07-07 | 2016-01-14 | Duke University | Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same |
| CA2954279C (en) | 2014-07-07 | 2023-11-14 | Duke University | Vaccines against an oncogenic isoform of esr1 and methods of using the same |
| AR101487A1 (en) | 2014-08-11 | 2016-12-21 | Hoffmann La Roche | CRYSTAL FORMS OF A STRATEGEN RECEIVER MODULATOR |
| US9980947B2 (en) | 2014-12-18 | 2018-05-29 | Genentech, Inc. | Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof |
| JP6807841B2 (en) | 2014-12-18 | 2021-01-06 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Estrogen receptor modulator and its use |
| EP3274476B1 (en) | 2015-03-25 | 2023-06-07 | The General Hospital Corporation | Digital analysis of circulating tumor cells in blood samples |
| US10053451B2 (en) | 2015-05-26 | 2018-08-21 | Genentech, Inc. | Heterocyclic estrogen receptor modulators and uses thereof |
| US9975856B2 (en) | 2015-10-07 | 2018-05-22 | Genentech, Inc. | Process for the preparation of (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid |
| CN108699024B (en) | 2015-12-09 | 2022-03-11 | 伊利诺伊大学评议会 | Benzothienyl selective estrogen receptor down-regulator compounds |
| CN108697779B (en) * | 2016-01-07 | 2023-09-19 | 杜克大学 | Cancer vaccine and delivery method |
| BR112018015419B1 (en) | 2016-02-05 | 2024-01-30 | Inventisbio Llc | SELECTIVE ESTROGEN RECEPTOR DEGRADANTS, THEIR USES, AND PHARMACEUTICAL COMPOSITION |
| SG10202007520WA (en) | 2016-03-02 | 2020-09-29 | Eisai R&D Man Co Ltd | Eribulin-based antibody-drug conjugates and methods of use |
| CA3018801C (en) * | 2016-03-25 | 2020-06-23 | Luoxin Biotechnology (Shanghai) Co., Ltd | Substituted-indole compounds as estrogen receptor down-regulators |
| JP7131773B2 (en) | 2016-04-29 | 2022-09-06 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | A targeted measure of transcriptional activity associated with hormone receptors |
| TWI808055B (en) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Combination therapies of hdac inhibitors and pd-1 inhibitors |
| TWI794171B (en) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Combination therapies of hdac inhibitors and pd-l1 inhibitors |
| US20180002344A1 (en) | 2016-06-16 | 2018-01-04 | Genentech, Inc. | Heteroaryl estrogen receptor modulators and uses thereof |
| US10695450B2 (en) | 2016-07-26 | 2020-06-30 | Laboratoires Cyclopharma | Synthesis of a radioactive agent composition |
| EP3500681B1 (en) * | 2016-08-18 | 2021-01-20 | Roche Diagnostics GmbH | Multiplex allele specific pcr assays for detection of estrogen receptor esr1 mutations |
| CN107814798B (en) * | 2016-09-14 | 2020-11-03 | 四川科伦博泰生物医药股份有限公司 | 3-substituted acrylic acid compound and preparation method and application thereof |
| US11224665B2 (en) | 2016-10-05 | 2022-01-18 | Duke University | Mitochondrial antiviral signaling (MAVS) protein compositions and methods of using the same |
| US10487143B2 (en) | 2016-10-05 | 2019-11-26 | Duke University | Vaccines against HER3 antigens and methods of using the same |
| BR112019007254A2 (en) * | 2016-10-11 | 2019-07-02 | Univ Duke | lasofoxifene treatment of breast cancer er + |
| WO2018081168A2 (en) | 2016-10-24 | 2018-05-03 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective mixed estrogen receptor downregulators |
| EP3985127A1 (en) * | 2016-10-27 | 2022-04-20 | The General Hospital Corporation | Digital analysis of blood samples to determine efficacy of cancer therapies for specific cancers |
| KR102576011B1 (en) | 2017-01-06 | 2023-09-06 | 쥐원 쎄라퓨틱스, 인크. | Combination therapy for the treatment of cancer |
| WO2018148576A1 (en) | 2017-02-10 | 2018-08-16 | G1 Therapeutics, Inc. | Benzothiophene estrogen receptor modulators |
| US20210094899A1 (en) * | 2017-07-28 | 2021-04-01 | Recurium Ip Holdings, Llc | Acrylic acid analogs |
| WO2019057201A1 (en) * | 2017-09-25 | 2019-03-28 | 罗欣生物科技（上海）有限公司 | Crystal form of estrogen receptor inhibitor and preparation method therefor |
| BR112020008888A2 (en) | 2017-11-16 | 2020-10-20 | Novartis Ag | combination therapies |
| TW201929902A (en) * | 2017-12-27 | 2019-08-01 | 美商提薩羅有限公司 | Methods of treating cancer |
| CN112261937B (en) | 2018-04-10 | 2023-11-14 | 杜克大学 | Lasofoxifene treatment of breast cancer |
| UA128114C2 (en) | 2018-06-21 | 2024-04-10 | Ф. Хоффманн-Ля Рош Аг | Solid forms of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2hpyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use |
| AR116109A1 (en) | 2018-07-10 | 2021-03-31 | Novartis Ag | DERIVATIVES OF 3- (5-AMINO-1-OXOISOINDOLIN-2-IL) PIPERIDINE-2,6-DIONA AND USES OF THE SAME |
| CN111184863B (en) * | 2018-11-15 | 2023-06-16 | 江苏恒瑞医药股份有限公司 | Use of a combination of a tyrosine kinase inhibitor, a CDK4/6 inhibitor and a SERD for the preparation of a medicament for the treatment of a tumour |
| JP7416540B2 (en) * | 2018-11-28 | 2024-01-17 | 羅欣薬業（上海）有限公司 | Salt form, crystal form of estrogen receptor downregulator and method for producing the same |
| WO2020128972A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| MX2021007687A (en) | 2018-12-24 | 2021-10-13 | Inventisbio Co Ltd | Novel salts of selective estrogen receptor degraders. |
| US20220144807A1 (en) | 2019-02-15 | 2022-05-12 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| CN113329792A (en) | 2019-02-15 | 2021-08-31 | 诺华股份有限公司 | Substituted 3- (1-oxoisoindolin-2-yl) piperidine-2, 6-dione derivatives and uses thereof |
| CA3136088A1 (en) | 2019-05-20 | 2020-11-26 | Matthew T. Burger | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
| CN110982807B (en) * | 2019-12-17 | 2022-04-29 | 云南农业大学 | High-efficiency stable cellulase mutant |
| US20230056470A1 (en) | 2019-12-20 | 2023-02-23 | Novartis Ag | Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases |
| KR20220151616A (en) * | 2020-03-06 | 2022-11-15 | 올레마 파마슈티컬스 인코포레이티드 | Methods of treating estrogen receptor-related diseases |
| EP4151636A4 (en) * | 2020-05-15 | 2024-02-28 | Simcere pharmaceutical co ltd | Pyrrolidine compound and use thereof |
| WO2021260528A1 (en) | 2020-06-23 | 2021-12-30 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| EP4188549A1 (en) | 2020-08-03 | 2023-06-07 | Novartis AG | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| AU2021388021A1 (en) | 2020-11-24 | 2023-06-22 | Novartis Ag | Anti-cd48 antibodies, antibody drug conjugates, and uses thereof |
| CA3202759A1 (en) | 2020-11-24 | 2022-06-02 | Novartis Ag | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
| EP4288434A1 (en) | 2021-02-02 | 2023-12-13 | Les Laboratoires Servier | Selective bcl-xl protac compounds and methods of use |
| TW202304979A (en) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES |
| WO2022245124A1 (en) * | 2021-05-18 | 2022-11-24 | 재단법인 대구경북첨단의료산업진흥재단 | Novel ethene compound and pharmaceutical composition including same as active ingredient for prevention or treatment of cancer |
| AR125874A1 (en) | 2021-05-18 | 2023-08-23 | Novartis Ag | COMBINATION THERAPIES |
| CN113293213A (en) * | 2021-06-17 | 2021-08-24 | 深圳华因康基因科技有限公司 | Primer probe for detecting breast cancer recurrence transfer gene HER2 amplification and application thereof |
| WO2023225336A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
| WO2023225320A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
| WO2024033513A1 (en) | 2022-08-11 | 2024-02-15 | Diaccurate | Compounds for treating cancer |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6060503A (en) * | 1991-12-02 | 2000-05-09 | Endorecherche, Inc. | Benzopyran-containing compounds and method for their use |
| DE60035522T2 (en) * | 1999-12-07 | 2008-03-20 | Sumitomo Chemical Co., Ltd. | MUTANT ER-ALPHA AND NUMBERING SYSTEMS FOR TRANSACTIVATION |
| ES2627692T3 (en) | 2010-06-10 | 2017-07-31 | Aragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
| GB2483736B (en) | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
| WO2013056178A2 (en) * | 2011-10-14 | 2013-04-18 | Foundation Medicine, Inc. | Novel estrogen receptor mutations and uses thereof |
| CA2857057A1 (en) | 2011-12-14 | 2013-06-20 | Seragon Pharmaceuticals, Inc. | Fluorinated estrogen receptor modulators and uses thereof |
| CA2857061A1 (en) * | 2011-12-16 | 2013-06-20 | Olema Pharmaceuticals, Inc. | Novel benzopyran compounds, compositions and uses thereof |
| NZ630124A (en) | 2012-03-20 | 2016-01-29 | Seragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
| MX2015011132A (en) * | 2013-03-14 | 2015-11-30 | Seragon Pharmaceuticals Inc | Polycyclic estrogen receptor modulators and uses thereof. |
| WO2014196863A1 (en) * | 2013-06-07 | 2014-12-11 | Keygene N.V. | Method for targeted sequencing |
| KR20160027968A (en) * | 2013-06-07 | 2016-03-10 | 라나 테라퓨틱스, 인크. | Compositions and methods for modulating foxp3 expression |
| MX2015017655A (en) | 2013-06-19 | 2016-04-15 | Seragon Pharmaceuticals Inc | Estrogen receptor modulator and uses thereof. |
| CA2915534A1 (en) | 2013-06-19 | 2014-12-24 | Seragon Pharmaceuticals, Inc. | Azetidine estrogen receptor modulators and uses thereof |
| JP2016540767A (en) | 2013-12-06 | 2016-12-28 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Estrogen receptor modulators for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer |
| EP3116497A2 (en) | 2014-03-13 | 2017-01-18 | F. Hoffmann-La Roche AG | Therapeutic combinations with estrogen receptor modulators |
-
2015
- 2015-03-12 AU AU2015228860A patent/AU2015228860A1/en not_active Abandoned
- 2015-03-12 EP EP15709908.6A patent/EP3116496A1/en not_active Withdrawn
- 2015-03-12 BR BR112016020953A patent/BR112016020953A2/en not_active Application Discontinuation
- 2015-03-12 JP JP2016557076A patent/JP2017509631A/en active Pending
- 2015-03-12 MA MA039740A patent/MA39740A/en unknown
- 2015-03-12 SG SG11201607339VA patent/SG11201607339VA/en unknown
- 2015-03-12 US US14/645,578 patent/US9855270B2/en not_active Expired - Fee Related
- 2015-03-12 CA CA2941161A patent/CA2941161A1/en not_active Abandoned
- 2015-03-12 MX MX2016011698A patent/MX2016011698A/en unknown
- 2015-03-12 RU RU2016137150A patent/RU2016137150A/en not_active Application Discontinuation
- 2015-03-12 WO PCT/EP2015/055120 patent/WO2015136017A1/en active Application Filing
- 2015-03-12 KR KR1020167025197A patent/KR20160132029A/en unknown
- 2015-03-12 CN CN201580025224.0A patent/CN106488767A/en active Pending
-
2016
- 2016-08-11 IL IL247250A patent/IL247250A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017509631A (en) | 2017-04-06 |
| US20150258099A1 (en) | 2015-09-17 |
| KR20160132029A (en) | 2016-11-16 |
| WO2015136017A1 (en) | 2015-09-17 |
| BR112016020953A2 (en) | 2018-01-23 |
| RU2016137150A3 (en) | 2018-10-19 |
| CA2941161A1 (en) | 2015-09-17 |
| AU2015228860A1 (en) | 2016-09-08 |
| MX2016011698A (en) | 2016-12-12 |
| RU2016137150A (en) | 2018-04-18 |
| CN106488767A (en) | 2017-03-08 |
| SG11201607339VA (en) | 2016-10-28 |
| MA39740A (en) | 2017-01-18 |
| US9855270B2 (en) | 2018-01-02 |
| EP3116496A1 (en) | 2017-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL247250A0 (en) | Methods and compositions for modulating estrogen receptor mutants | |
| HK1247199A1 (en) | Estrogen receptor modulators and uses thereof | |
| IL273058A (en) | Compositions and methods for modulating pkk expression | |
| HK1257295A1 (en) | Compositions and methods for immunooncology | |
| IL272653A (en) | Compositions and methods for modulating growth hormone receptor expression | |
| HK1243333A1 (en) | Methods and compositions for modified t cells | |
| IL249373A0 (en) | Formulated receptor polypeptides and related methods | |
| IL271659A (en) | Compositions and methods for modulating complement factor b expression | |
| EP3183349A4 (en) | Methods for preparing rebaudioside i and uses | |
| IL246879A0 (en) | Apilimod compositions and methods for using same | |
| EP3212315A4 (en) | Compositions and methods for forming emulsions | |
| GB201507781D0 (en) | Blending techniques for curve fitting | |
| IL268684A (en) | Compositions and methods for immunooncology | |
| GB201417828D0 (en) | New methods and compositions | |
| EP3094323A4 (en) | Methods and compositions for modulating hormone levels | |
| IL274524A (en) | Compositions and methods for aquaculturing | |
| EP3137624A4 (en) | Compositions and methods for modulating mtorc1 | |
| IL249203A0 (en) | Androgen receptor modulators and methods for their use | |
| SG11201702475VA (en) | Methods and compositions for modulating th-gm cell function | |
| EP3227249A4 (en) | Compositions and methods for micronutrient introduction | |
| PL3113774T3 (en) | Compositions of grapiprant and methods for using the same | |
| EP3224230A4 (en) | Estrogen receptor modulators | |
| GB201405403D0 (en) | Receptor modulation |